Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Zinc finger protein 417 (ZNF417)** is a primate-specific, KRAB (Krüppel-associated box) domain-containing zinc finger transcription factor predicted to function as a sequence-specific transcriptional repressor active in the nucleus[1][3][4]. ZNF417 regulates gene expression by binding to sequence-specific DNA motifs in the regulatory regions of target genes, notably repressing human endogenous retrovirus K (HERVK) and SVA retroelements through the recruitment of epigenetic silencers like KAP1 and SETDB1, thereby enforcing heterochromatic silencing[2][4]. It likely acts in concert with its close paralog ZNF587, sharing high sequence similarity and overlapping binding preferences[2][4]. ZNF417 is not a classic therapeutic target (such as a receptor, enzyme, ion channel, or transporter). Its described disease association is limited to rare genetic findings in Glycogen Storage Disease IXb, and it has not been directly implicated as a biomarker, drug target, or as having specific safety considerations[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 417 (ZNF417).